LegalZoom.com, Inc. (LZ)
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Investigation
06/03/2021
Initial Lawsuit
06/03/2021
Lawsuit Progression
03/21/2022
Investigation regarding Frequency’s Phase 2a clinical trial of its hearing loss treatment titled as a potential treatment for patients with severe sensorineural hearing loss (SNHL) and subsequent disappointing results.
03/23/2021
Frequency releases data from its Phase 2a study of FX-322-202 showing that “four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo.”
“In the four-arm Phase 2a study, 95 subjects aged 18-65 were evaluated for hearing improvement using Word Recognition (WR), Words-In-Noise (WIN), pure tone audiometry and additional exploratory measures. All subjects were administered a total of four weekly intratympanic injections comprised of zero, one, two, or four doses of FX-322 with the balance of injections comprised of placebo doses.
While WR scores increased across all groups, repeated weekly injections appeared to dampen the hearing benefit observed compared to other single-injection studies. The Phase 2a interim results also showed an unexpected apparent level of hearing benefit in the placebo group that did not occur in previous trials and exceeded well-established published standards, potentially suggesting bias due to trial design. Given these challenges observed in the Phase 2a study design, there was no discernible hearing benefit of FX-322 over placebo.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$7.99 | $36.29 | $-28.3 | -77.98% |
This is a federal securities action on behalf of a class consisting of all persons who purchased or otherwise acquired Frequency’s common stock between November 16, 2020, and March 22, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) deceive the investing public, including Plaintiff and other Class members, as alleged herein;
(ii) artificially inflate and maintain the market price of Frequency’s common stock;
(iii) cause Plaintiff and other members of the Class to purchase or otherwise acquire Frequency’s common stock at artificially inflated prices.
03/21/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.